This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van den Oord, J. J. Articles by De Wolf-Peeters, C. Search for Related Content PubMed PubMed Citation Articles by van den Oord, J. J. Articles by De Wolf-Peeters, C.

American Journal of Pathology, Vol 145, 294-300, Copyright © 1994 by American Society for Investigative Pathology

REGULAR ARTICLES

Bcl-2 expression in human melanocytes and melanocytic tumors

JJ van den Oord, N Vandeghinste, M De Ley and C De Wolf-Peeters
Department of Pathology, University Hospital St. Raphael, Leuven, Belgium.

During an immunohistochemical study of the distribution of the Bcl-2 proto-oncogene product in frozen sections of normal human skin, a hitherto unrecognized strong reactivity with melanocytes was observed. This prompted us to study Bcl-2 expression in a variety of pigment lesions. In nevocellular nevi, immunoreactivity gradually diminished or even disappeared toward the deeper dermal component. In malignant melanomas of all stages and histological subtypes, the neoplastic cells expressed Bcl-2 oncoprotein, the most intense positivity being restricted to cells in the radial growth phase. Cutaneous and lymph node metastases of malignant melanomas were negative or showed only weak and focal reactivity. The specificity of the staining was confirmed by Western blotting of tissue lysates. The loss of Bcl-2 expression in the deeper parts of nevi may offer an explanation for the "maturation" and final disappearance of dermal nevocellular nevi. The expression of Bcl-2 oncoprotein by malignant melanomas adds these neoplasms to a growing list of tumors expressing this oncoprotein. Bcl- 2 in malignant melanoma may play a role in tumor development by sparing the cells from apoptotic death (and thereby exposing them to secondary events) or through cooperation with other oncogenes. The lack of reactivity in metastatic melanoma suggests that mechanisms other than Bcl-2 are involved in the survival and growth of metastatic melanoma cells.

This article has been cited by other articles:

				L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]

				K. A. DiVito, A. J. Berger, R. L. Camp, M. Dolled-Filhart, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma Cancer Res., December 1, 2004; 64(23): 8773 - 8777. [Abstract] [Full Text] [PDF]

				H. Rossiter, S. Beissert, C. Mayer, M. P. Schön, B. G. Wienrich, E. Tschachler, and T. S. Kupper Targeted Expression of bcl-2 to Murine Basal Epidermal Keratinocytes Results in Paradoxical Retardation of Ultraviolet- and Chemical-induced Tumorigenesis Cancer Res., May 1, 2001; 61(9): 3619 - 3626. [Abstract] [Full Text]

				D. Jean, J. E. Gershenwald, S. Huang, M. Luca, M. J. Hudson, M. A. Tainsky, and M. Bar-Eli Loss of AP-2 Results in Up-regulation of MCAM/MUC18 and an Increase in Tumor Growth and Metastasis of Human Melanoma Cells J. Biol. Chem., June 26, 1998; 273(26): 16501 - 16508. [Abstract] [Full Text] [PDF]